预测痴呆症的疾病特异性风险模型:一个总体审查
Eugene Yee Hing Tang1, Jacob Brain2,3, Serena Sabatini4
1Population Health Sciences Institute, Newcastle University, Newcastle NE2 4HH, UK.
Life (Basel, Switzerland)
|November 27, 2024
概括
开发针对特定疾病群体 (如糖尿病) 量身定制的痴呆风险预测模型可能会提高准确性. 目前的模型往往没有考虑疾病特异性风险因素,强调需要个性化方法来评估痴呆风险.
科学领域:
- 神经科学是一个神经科学.
- 流行病学 流行病学
- 医学统计 医学统计
背景情况:
- 痴呆症是一个重大的全球健康挑战,心血管,心脏代谢和脑血管疾病患者的风险增加.
- 现有的痴呆症预测模型通常不适合特定疾病群体,可能会限制其准确性.
研究的目的:
- 审查和综合现有关于痴呆风险预测模型的文献,特别关注有病史的个人.
- 探索疾病特异性痴呆风险模型的开发和验证.
主要方法:
- 对三项先前的关于痴呆风险模型开发和测试的系统性审查进行了系统性审查.
- 包括九项符合痴呆症风险预测在疾病特定人群的特定标准的研究.
主要成果:
- 疾病特异性痴呆风险模型主要是为糖尿病患者开发的,利用人口统计学,疾病特异性和并发症数据.
- 像CHA2DS2-VASc和CHADS2这样的现有模型已经在患有心房动和心力衰竭的患者中显示出痴呆症结局的外部验证.
- 一个全人口痴呆风险模型在中风子样本中显示出类似的预测准确性,这表明疾病状况的重要性.
结论:
- 将痴呆风险预测模型定制为特定疾病群体对于提高准确性至关重要.
- 疾病状况和相关风险因素是开发有效痴呆症预测工具的重要考虑因素.
- 对疾病特异性风险建模的进一步研究是有必要的,以改善痴呆症预防和管理策略.
更多相关视频
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
7.0K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
相关概念视频
Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
